Bacterial Chassis Pathway Balancing Patents: Top Filers & Trends 2026
- 38.9% of all 234 records sit with just five assignees, while the ranked list runs to 100 companies with a long single-filing tail behind them.
- Filings peaked in 2022 at 24 then eased 11% from 19 (2021) to 17 (2024) — a plateau, not a decline, once the publication lag is accounted for.
- C12P fermentation claims cover 62.8% of records against near-universal C12N genetic-engineering claims (99.1%), leaving fertiliser and therapeutic-activity classes each under 10%.
Filing growth compares 2021 (19 records) with 2024 (17) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 234 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
This landscape covers 234 published records filed between 2015 and 2026 that combine bacterial host cell or engineered/recombinant bacterium claims with metabolic flux, enzyme ratio, pathway bottleneck, precursor supply or byproduct suppression language, classified under C12N15/09, C12N1/20 or C12Q1/68. It is a search built around pathway balancing specifically — controlling relative flux through competing enzymatic steps — rather than bacterial engineering broadly.
Filing activity spans genetic engineering method claims, fermentation-process claims, and a smaller set of measurement, peptide and therapeutic-activity claims layered on top of the same host-cell art. Publication lags filing by roughly 18 months industry-wide, so the most recent one to two years of any such dataset always understate true filing activity.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trends and technology composition
The dataset spans 234 published records filed between 2015 and 2026, with publication lagging filing by roughly 18 months, so the final one to two years always undercount true filing activity.
Filing activity peaked in 2022, plateau since
Filings rose from 9 in 2017 to a peak of 24 in 2022. Across the most recent complete span, 2021 (19) to 2024 (17), filings fell 11%, a modest pull-back rather than a collapse; 2025 and 2026 figures are still filling in under the publication lag.
Fermentation and genetic engineering dominate the classification mix
C12N (microorganisms and genetic engineering) appears on 99.1% of the 234 records, and C12P (fermentation and enzymatic synthesis) on 62.8%, confirming that pathway balancing claims are filed overwhelmingly as strain-engineering plus fermentation-process combinations. Peptide/protein claims (C07K, 28.6%) and measuring/testing claims (C12Q, 15.0%) trail well behind, with fertiliser (C05F) and therapeutic-activity (A61P) classes each under 10%.
Shares are the percentage of the 234 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Bacterial Chassis Pathway Balancing with Eureka
This page is one run against one query. Ask Eureka your own question about bacterial chassis pathway balancing and every answer comes back with the patent numbers behind it.
Try EurekaRepresentative and most-cited filings
EP1415160A2 — whole-cell mutagenesis and combinatorial evolution
An invention comprising cellular transformation, directed evolution, and screening methods for creating novel transgenic organisms having desirable properties. In one embodiment, this invention provides a method of generating a transgenic organism, such as a microbe or a plant, having a plurality of traits that are differentially activatable. This invention also provides a method of retooling genes and gene pathways by the introduction of regulatory sequences, such as promoters, that are operable in an intended host, this conferring operability to a novel gene pathway when it is introduced into an intended host.Filed by Verenium Corporation, 2004-05-06. Closely related to US20050124010A1 and US7033781B1, the two most-cited records in this corpus.
View full filing in Eureka| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20050124010A1 | Whole cell engineering by mutagenizing a substantial portion of a starting genome combining mutations and opt… | 268 |
| 2 | US7659097B2 | Production of isoprenoids | 173 |
| 3 | US7033781B1 | Whole cell engineering by mutagenizing a substantial portion of a starting genome, combining mutations, and o… | 120 |
| 4 | US4743679A | Process for producing human epidermal growth factor and analogs thereof | 96 |
| 5 | US20040072323A1 | Diterpene-producing unicellular organism | 93 |
| 6 | WO2009036095A1 | Engineered light-harvesting organisms | 86 |
| 7 | WO2019084342A1 | Gene targets for nitrogen fixation targeting for improving plant traits | 48 |
| 8 | WO2001007567A1 | Engineering of metabolic control | 48 |
| 9 | US20110053216A1 | Modified Cyanobacteria | 45 |
| 10 | US20200331820A1 | Gene targets for nitrogen fixation targeting for improving plant traits | 39 |
Citation counts favour older filings within a searched corpus and should be read as a signal of influence, not of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the filing data signals
Three patterns stand out once filing volume, classification spread and citation weight are read together: concentration at the top, a plateau rather than a drop in recent filings, and a technology mix still anchored in classical fermentation strain engineering.
A concentrated top with a long tail beneath it
The leader holds 32 records and the top ten together hold 57.7% of the 234 records in scope, but the ranking runs to 100 companies, meaning most participants hold only a handful of filings each.
A plateau after the 2022 peak, not a downturn
Filings peaked at 24 in 2022 and eased to 17 by 2024. Because publication lags filing by roughly 18 months, 2025 and 2026 counts are still incomplete and should not be read as a trend continuation.
Fermentation-process claims dominate over measurement or therapeutic claims
C12N genetic-engineering claims appear on 99.1% of records and C12P fermentation claims on 62.8%, while measuring/testing (C12Q, 15.0%) and therapeutic-activity (A61P, 6.4%) classes remain minority shares.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to bacterial chassis pathway balancing, with the prior art for and against each one.
Who is filing, and what is still open
The ranked list covers 100 assignees across the 234 records in scope. Filing is concentrated at the top but far from closed: most of the ranking holds only a handful of records each, and several of the technology's adjacent branches remain lightly claimed.
A single leader well ahead of the field
The top-ranked assignee holds 32 of the 234 records in scope, roughly three times the fifth-place holder's 11, indicating a clear leader rather than a tightly bunched top group.
Top ten hold more than half the field
The ten largest filers together account for 57.7% of the 234 records in scope, while the remaining 90 ranked assignees split the rest, mostly in small single-digit counts.
A handful of recurring co-filing relationships
Ten co-assignee pairs appear in the dataset, the strongest linking a UK research and innovation body with a genomics engineering firm on 11 shared records, and a New Zealand-based gas fermentation company with a university partner on 8.
| Assignee | Recent year | YoY |
|---|---|---|
| Pivot Bio, Inc. | 0 | — |
| Chr. Hansen HMO GmbH | 0 | — |
| Food Industry Research and Development Institute | 0 | — |
| LanzaTech NZ, Inc. | 0 | — |
| United Kingdom Research and Innovation | 0 | — |
| Scarab Genomics, LLC | 0 | — |
| University of Queensland | 0 | — |
| Deinove SA | 0 | — |
Where to take this analysis
The filing data points to three practical next steps for teams working on bacterial chassis pathway balancing.
Check freedom-to-operate against the whole-genome mutagenesis cluster
US20050124010A1, US7033781B1 and EP1415160A2 form a closely related, heavily-cited family of broad genome-engineering method claims. Any strain-development programme using iterative genome-wide mutagenesis and recombination should map its process against this cluster before committing to a route.
Map claim scope in EurekaEvaluate the under-claimed fertiliser and therapeutic branches
C05F and A61P classes each sit under 10% of the 234 records in scope despite technical adjacency to the fermentation core. Teams building byproduct valorisation or therapeutic-output strains may find more open claim space here than in the core fermentation art.
Explore white space in EurekaTrack the top assignees' filing cadence past 2024
With 2025-2026 filings still filling in under the publication lag, watching how the current leaders and the strongest co-filing pairs behave once that data completes will show whether the 2022 peak was a high point or a new normal.
Set up monitoring in EurekaCommon questions on bacterial chassis pathway balancing patents
It refers to methods that control the relative flux through competing enzymatic steps in an engineered metabolic pathway, typically by adjusting enzyme expression ratios, precursor supply, or suppressing byproduct-forming branches. In patent terms this shows up as claims combining a host bacterial cell, a defined set of pathway enzymes, and a stated ratio or control mechanism rather than a single gene insertion. The search terms behind this dataset — metabolic flux, enzyme ratio, pathway bottleneck, precursor supply, byproduct suppression — map directly onto how these claims are drafted.
The assignee ranking covers 100 companies across the 234 records in scope, with the leader holding 32 records and the field concentrated at the top: the five largest filers together account for 38.9% of all 234 records, and the ten largest for 57.7%. Beyond that top group there is a long tail of single- or few-filing entrants, which is typical of a field still absorbing academic spinouts and smaller synthetic-biology companies alongside a handful of established players.
Filings rose through the late 2010s to a peak of 24 records in 2022, then eased to 17 by 2024 — an 11% decline across that 2021-to-2024 span. That should not be read as the field cooling, because publication lags filing by roughly 18 months, meaning 2025 and 2026 figures in any such dataset are still incomplete. The safest reading is a mature but still active filing base rather than a field in decline.
Relative to the fermentation and genetic-engineering core, classes tied to fertiliser and waste-derived applications (C05F, 9.8% of 234 records) and therapeutic activity (A61P, 6.4%) carry far fewer filings. Given that bacterial chassis work increasingly intersects with agricultural byproduct valorisation and therapeutic protein production, these branches look under-claimed relative to their technical adjacency to the core fermentation art. Regional filing gaps, such as India's 9 records against the United States' 65, point to similar white space by geography rather than technology alone.
US20050124010A1, a whole-cell engineering method built on genome-scale mutagenesis, combination and repeated evolution cycles, is cited 268 times in this corpus, making it the most influential single record. Its closely related filings, US7033781B1 and EP1415160A2, describe essentially the same method and together indicate that broad, iterative genome-engineering approaches — rather than narrow single-pathway claims — have shaped the foundational claim scope that later filers have had to navigate around.
Research Bacterial Chassis Pathway Balancing in depth with Eureka
Go past this page: query the whole bacterial chassis pathway balancing corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.